Announced details
Multiple myeloma, cellular immunotherapy, hematology
The disclosure states that the therapy induced tumour-specific T-cell immunity in a nonclinical model. Quantitative figures: Not disclosed.
The host organisation of the conference at which the Company will present its research results. No capital, personnel or business relationship is stated.
An organisation that hosts an international conference in the field of hematology. ASH 2026 will be held in New Orleans, United States, and is stated to attract more than 30,000 researchers and healthcare professionals from around the world each year.
New Orleans, United States (venue for ASH 2026)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
The 68th American Society of Hematology Annual Meeting (ASH 2026), hosted by the American Society of Hematology (ASH)
| Item | Details |
|---|---|
| Names of Products / Services Covered | iPS cell-derived BCMA CAR-NKT cell therapy (BP2202) |
| Counterparty | American Society of Hematology (ASH) |
| Counterparty overview | An organisation that hosts an international conference in the field of hematology. ASH 2026 will be held in New Orleans, United States, and is stated to attract more than 30,000 researchers and healthcare professionals from around the world each year. |
| Relationship with the Company | The host organisation of the conference at which the Company will present its research results. No capital, personnel or business relationship is stated. |
| Launch date | Scheduled for 6:00 p.m. to 8:00 p.m. Central Time on 14 December 2026 (Monday). In Japan time, this is 9:00 a.m. to 11:00 a.m. on 15 December 2026 (Tuesday). |
| Applicable area | Multiple myeloma, cellular immunotherapy, hematology |
| Location | New Orleans, United States (venue for ASH 2026) |
| Location scale | More than 30,000 researchers and healthcare professionals attend each year |
| Quantitative Effects | The disclosure states that the therapy induced tumour-specific T-cell immunity in a nonclinical model. Quantitative figures: Not disclosed. |
| Source | The 68th American Society of Hematology Annual Meeting (ASH 2026), hosted by the American Society of Hematology (ASH) |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To demonstrate that BP2202 showed the same activity of inducing tumour-specific T-cell immunity in a nonclinical model of multiple myeloma, the target disease for its US Phase 1 clinical trial.